Yuan Hang, Reddy Marpadga A, Deshpande Supriya, Jia Ye, Park Jung Tak, Lanting Linda L, Jin Wen, Kato Mitsuo, Xu Zhong Gao, Das Sadhan, Natarajan Rama
1 Department of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope , Duarte, California.
2 Department of Nephrology, First Hospital of Jilin University , Changchun, China .
Antioxid Redox Signal. 2016 Mar 1;24(7):361-75. doi: 10.1089/ars.2015.6372. Epub 2015 Nov 30.
Epigenetic mechanisms, including histone post-translational modifications and DNA methylation, are implicated in the pathogenesis of diabetic nephropathy (DN), but the mediators are not well known. Moreover, although dyslipidemia contributes to DN, epigenetic changes triggered by lipids are unclear. In diabetes, increased expression of 12/15-lipoxygenase (12/15-LO) enhances oxidized lipids such as 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE], which promote oxidant stress, glomerular and mesangial cell (MC) dysfunction, and fibrosis, and mediate the actions of profibrotic growth factors. We hypothesized that 12/15-LO and its oxidized lipid products can regulate epigenetic mechanisms mediating profibrotic gene expression related to DN.
12(S)-HETE increased profibrotic gene expression and enrichment of permissive histone lysine modifications at their promoters in MCs. 12(S)-HETE also increased protein levels of SET7, a histone H3 lysine 4 methyltransferase, and promoted its nuclear translocation and enrichment at profibrotic gene promoters. Furthermore, SET7 (Setd7) gene silencing inhibited 12(S)-HETE-induced profibrotic gene expression. 12/15-LO (Alox15) gene silencing or genetic knockout inhibited transforming growth factor-β1 (TGF-β1)-induced expression of Setd7 and profibrotic genes and histone modifications in MCs. Furthermore, 12/15-LO knockout in mice ameliorated key features of DN and abrogated increases in renal SET7 and profibrotic genes. Additionally, 12/15-LO siRNAs in vivo blocked increases in renal SET7 and profibrotic genes in diabetic mice.
These novel results demonstrate for the first time that 12/15-LO-derived oxidized lipids regulate histone modifications associated with profibrotic gene expression in MCs, and 12/15-LO can mediate similar actions of TGF-β1 and diabetes. Targeting 12/15-LO might be a useful strategy to inhibit key epigenetic mechanisms involved in DN.
表观遗传机制,包括组蛋白翻译后修饰和DNA甲基化,与糖尿病肾病(DN)的发病机制有关,但其中介因子尚不清楚。此外,尽管血脂异常会导致DN,但脂质引发的表观遗传变化尚不清楚。在糖尿病中,12/15-脂氧合酶(12/15-LO)表达增加会增强氧化脂质,如12(S)-羟基二十碳四烯酸[12(S)-HETE],后者会促进氧化应激、肾小球和系膜细胞(MC)功能障碍及纤维化,并介导促纤维化生长因子的作用。我们推测12/15-LO及其氧化脂质产物可调节介导与DN相关的促纤维化基因表达的表观遗传机制。
12(S)-HETE增加了MC中促纤维化基因的表达及其启动子处允许性组蛋白赖氨酸修饰的富集。12(S)-HETE还增加了组蛋白H3赖氨酸4甲基转移酶SET7的蛋白水平,并促进其核转位及在促纤维化基因启动子处的富集。此外,SET7(Setd7)基因沉默抑制了12(S)-HETE诱导的促纤维化基因表达。12/15-LO(Alox15)基因沉默或基因敲除抑制了转化生长因子-β1(TGF-β1)诱导的MC中Setd7和促纤维化基因的表达以及组蛋白修饰。此外,小鼠中12/15-LO基因敲除改善了DN的关键特征,并消除了肾脏中SET7和促纤维化基因的增加。此外,体内12/15-LO siRNA可阻止糖尿病小鼠肾脏中SET7和促纤维化基因的增加。
这些新结果首次证明,12/15-LO衍生的氧化脂质可调节与MC中促纤维化基因表达相关的组蛋白修饰,并且12/15-LO可介导TGF-β1和糖尿病的类似作用。靶向12/15-LO可能是抑制DN中关键表观遗传机制的有用策略。